Clinical trial
Phase II Study of Capecitabine and Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients With Failure on Interleukin-2 Based Regimens
NCT00591188 is registered in ClinicalTrials.gov with Kidney Cancer Research Bureau as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Study of Capecitabine and Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients With Failure on Interleukin-2 Based Regimens
- Lead sponsor
- Kidney Cancer Research Bureau
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 31, 2006
- Completion date
- Not reported
- Enrollment
- 49 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.